NO20083524L - Foam-forming preparation - Google Patents

Foam-forming preparation

Info

Publication number
NO20083524L
NO20083524L NO20083524A NO20083524A NO20083524L NO 20083524 L NO20083524 L NO 20083524L NO 20083524 A NO20083524 A NO 20083524A NO 20083524 A NO20083524 A NO 20083524A NO 20083524 L NO20083524 L NO 20083524L
Authority
NO
Norway
Prior art keywords
present
foam
composition
relates
forming composition
Prior art date
Application number
NO20083524A
Other languages
Norwegian (no)
Inventor
Francois Jean-Louis Boutignon
Jean-Marc Aiache
Thomas Jean Henri Barres
Florian Tapissier
Original Assignee
Disphar Internat Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06100572A external-priority patent/EP1810666A1/en
Application filed by Disphar Internat Bv filed Critical Disphar Internat Bv
Publication of NO20083524L publication Critical patent/NO20083524L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

Foreliggende oppfinnelse vedrører et nytt skumdannende preparat som er passende til rektal administrering av lokalt virkende, farmasøytiske ingredienser, og produktet tilpasset til å administrere nevnte skumdannende preparat. Foreliggende oppfinnelse vedrører også en fremgangsmåte for dens fremstilling. Ifølge foreliggende oppfinnelse blir et skumdannende preparat tilveiebrakt som oppviser et høyt ekspansjonsforhold og som samtidig overfører optimal fremtoning av det dannede skummet for å tillate tilstrekkelig kontakttid for den aktive ingrediensen på målstedet i tarmen for å oppnå optimal lokal effekt. Preparatet ifølge foreliggende oppfinnelse tilveiebringer overlegne egenskaper for behandlingen av rektale sykdommer.The present invention relates to a new foam-forming composition suitable for rectal administration of locally acting pharmaceutical ingredients, and to the product adapted to administer said foam-forming composition. The present invention also relates to a process for its preparation. According to the present invention, a foaming composition is provided which exhibits a high expansion ratio and at the same time transmits optimum appearance of the formed foam to allow sufficient contact time for the active ingredient at the target site in the intestine to obtain optimal local effect. The composition of the present invention provides superior properties for the treatment of rectal diseases.

NO20083524A 2006-01-19 2008-08-13 Foam-forming preparation NO20083524L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06100572A EP1810666A1 (en) 2006-01-19 2006-01-19 Foam-Forming composition
US76177906P 2006-01-25 2006-01-25
PCT/EP2007/000271 WO2007082698A1 (en) 2006-01-19 2007-01-12 Foam-forming composition

Publications (1)

Publication Number Publication Date
NO20083524L true NO20083524L (en) 2008-08-13

Family

ID=37831688

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083524A NO20083524L (en) 2006-01-19 2008-08-13 Foam-forming preparation

Country Status (6)

Country Link
EP (1) EP1981480A1 (en)
JP (1) JP5184373B2 (en)
AU (1) AU2007207116B2 (en)
CA (1) CA2637408C (en)
NO (1) NO20083524L (en)
WO (1) WO2007082698A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
MXPA05004278A (en) 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US20090239289A1 (en) * 2008-03-19 2009-09-24 Ipser Reid M Drain Foam Composition and Method of Using the Same
WO2009150530A2 (en) * 2008-06-11 2009-12-17 Ferring International Center Sa Novel foam composition
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2776474C (en) 2009-10-02 2021-01-12 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
JP2015168654A (en) * 2014-03-07 2015-09-28 三笠製薬株式会社 Aqueous composition for nsaids containing foaming formulation
MX2020012139A (en) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Compositions and methods for treating rosacea and acne.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9000485D0 (en) * 1990-02-09 1990-02-09 Pharmacia Ab FOAMABLE COMPOSITION FOR PHARMACEUTICAL USE, USE THEREOF AND METHOD OF TREATMENT
IT1243379B (en) * 1990-07-27 1994-06-10 Giuliani Spa PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL
FR2713486B1 (en) * 1993-12-14 1996-02-09 Scophysa New compositions for foams, in particular rectal foams, and foams thus obtained.
GB9414699D0 (en) * 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
SE9703226D0 (en) * 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
MXPA05004278A (en) * 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US20050069499A1 (en) * 2003-09-25 2005-03-31 Moshe Arkin Foamable compositions, processes of preparing same and uses thereof

Also Published As

Publication number Publication date
EP1981480A1 (en) 2008-10-22
JP2009523745A (en) 2009-06-25
AU2007207116A1 (en) 2007-07-26
AU2007207116B2 (en) 2012-08-02
JP5184373B2 (en) 2013-04-17
CA2637408A1 (en) 2007-07-26
WO2007082698A1 (en) 2007-07-26
CA2637408C (en) 2013-12-03

Similar Documents

Publication Publication Date Title
NO20083524L (en) Foam-forming preparation
JP6865743B2 (en) Compounds useful as activity regulators of TRPM8
Dawson et al. The role of 5-HT1A and 5-HT1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (±) pindolol
MY143795A (en) Tetrahydropyridoindole derivatives
NO20092529L (en) Substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for the treatment of hyperproliferative disorders and diseases associated with angiogenesis
BRPI0513455A (en) flavor masking formulation comprising the drug in a delayed dissolution form and / or cyclodextrin in an improved dissolution form
WO2008134828A3 (en) Tissue degeneration protection
ATE470443T1 (en) INDOL-1-YL ACID DERIVATIVES
NO20071354L (en) use of the same Butylphthalide self-emulsifying drug delivery system, as well as methods of preparing and using the same.
ATE500817T1 (en) FOAMABLE COMPOSITION SUBSTANTIALLY FREE OF PHARMACEUTICALLY ACTIVE INGREDIENTS FOR THE TREATMENT OF HUMAN SKIN
BRPI0819690B8 (en) use of a composition comprising cysteamine or cystamine, or a pharmaceutically acceptable salt thereof
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
NO20073959L (en) Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth
ATE520668T1 (en) SIGMARECEPTOR INHIBITORS
UA97794C2 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
NO20083905L (en) New pyron-indole derivatives and process for their preparation
US20080261984A1 (en) Use of S,S-Reboxetine in the Treatment of Pain
WO2011074015A3 (en) Composition of pharmaceutical product to treat sexual dysfunction
WO2008008701A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
WO2010017343A3 (en) Flupirtine hydrochloride maleic acid cocrystal
CO2023011781A2 (en) Pharmaceutical dosage forms comprising (4s)–24–chloro–4–ethyl–73–fluoro–35–methoxy–32,5–dioxo–14–(trifluoromethyl)–32h–6–aza–3(4,1) –pyridine–1(1)–[1,2,3]triazole–2(1,2),7(1)–dibenzeneheptaphane–74–carboxamide
WO2011060253A3 (en) Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
EA200970122A1 (en) PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORMS OF MALEAT FLYUPIRTIN

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application